
|Videos|July 18, 2018
Efficacy of Nivolumab in Patients With Melanoma
Author(s)Paolo A. Ascierto, MD
Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma.
Advertisement
Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma.
According to Ascierto, this agent has proven to be safe and efficacious in this patient population. The incidence of grade 3/4 adverse events (AEs) is also low.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at SABCS 2025
2
Considering Role of PD-L1 CPS in Frontline Gastric Cancer Treatment
3
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
4
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
5










































